Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT02289209 is registered in ClinicalTrials.gov with Dan Zandberg as lead sponsor.

NCT NCT02289209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02289209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Lead sponsor
Dan Zandberg
Phase
Phase 2
Overall status
Completed
Start date
March 9, 2016
Completion date
August 31, 2024
Enrollment
48 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell of head and neck, recurrent head and neck cancer